CME: Expert Answers to Common Questions for the Management of Hemophilia A

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Expert Answers to Common Questions for the Management of Hemophilia A

Expert Answers to Common Questions for the Management of Hemophilia A
Could newly approved, unique agents mark a turning point for our patients with Hemophilia A?

Available credits: 0.50

Time to complete: 30 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life.

    Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices.

    AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on hemophilia A.


  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Apply the latest safety and efficacy data for newly approved and emerging agents in clinical decision making for the treatment of hemophilia A
    • Devise strategies for testing, monitoring, and treatment of inhibitors, based on guideline recommendations
  • Target Audience

    This activity is intended for community-based hematologists, hemophilia specialists, nurses, fellows, pharmacists, social workers, orthopedic, pediatric, lab, and other allied healthcare professionals as part of the interdisciplinary care team involved with optimizing patient outcomes in hemophilia A management.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Eric H. Kraut, MD, reported a financial interest/relationship or affiliation in the form of Advisor, Analym Pharmaceuticals; Ownership interest, Pfizer, Inc.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers: Jocelyn Timko, BS and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Linda Gracie-King, MS (spouse) reports a financial interest/relationship or affiliation in the form of Common stock: Exelixis. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Accreditation and Credit Designation Statements


    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit JA4008106-9999-19-022-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by     

  • Commercial Support

    Supported by an educational grant from Genentech.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 12/11/19